Compile Data Set for Download or QSAR
maximum 50k data
Found 1038 of ic50 data for polymerid = 580,584,6044
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM556317(US11345702, Table 1.35 | US20230390274, Compound A...)
Affinity DataIC50:  0.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM556286(US11345702, Table 1.4 | US20230390274, Compound A-...)
Affinity DataIC50:  0.600nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347359(US10301320, ID SW033291 | US10869871, ID # SW03329...)
Affinity DataIC50:  0.760nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347364(US10301320, ID SW206980 | US10869871, ID # SW20698...)
Affinity DataIC50:  0.970nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347364(US10301320, ID SW206980 | US10869871, ID # SW20698...)
Affinity DataIC50:  0.970nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347365(US10301320, ID SW206992 | US10869871, ID # SW20699...)
Affinity DataIC50:  0.970nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347364(US10301320, ID SW206980 | US10869871, ID # SW20698...)
Affinity DataIC50:  0.970nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347364(US10301320, ID SW206980 | US10869871, ID # SW20698...)
Affinity DataIC50:  0.970nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266191(CHEMBL4072253)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266223(CHEMBL4060121)
Affinity DataIC50:  1nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347384(US10869871, ID # SW208436 | US20230285402, ID # SW...)
Affinity DataIC50:  1.14nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347384(US10869871, ID # SW208436 | US20230285402, ID # SW...)
Affinity DataIC50:  1.14nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347384(US10869871, ID # SW208436 | US20230285402, ID # SW...)
Affinity DataIC50:  1.14nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347359(US10301320, ID SW033291 | US10869871, ID # SW03329...)
Affinity DataIC50:  1.23nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347359(US10301320, ID SW033291 | US10869871, ID # SW03329...)
Affinity DataIC50:  1.23nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347429(US10869871, ID # SW209415 | US20230285402, ID # SW...)
Affinity DataIC50:  1.30nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347429(US10869871, ID # SW209415 | US20230285402, ID # SW...)
Affinity DataIC50:  1.30nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347429(US10869871, ID # SW209415 | US20230285402, ID # SW...)
Affinity DataIC50:  1.30nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347429(US10869871, ID # SW209415 | US20230285402, ID # SW...)
Affinity DataIC50:  1.30nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266122(CHEMBL4070789)
Affinity DataIC50:  1.30nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347379(US10869871, ID # SW211668-(33291-R | US20230285402...)
Affinity DataIC50:  1.34nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347379(US10869871, ID # SW211668-(33291-R | US20230285402...)
Affinity DataIC50:  1.34nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347379(US10869871, ID # SW211668-(33291-R | US20230285402...)
Affinity DataIC50:  1.34nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347368(US10301320, ID SW208066 | US10869871, ID # SW20806...)
Affinity DataIC50:  1.37nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347391(US10869871, ID # SW208496 | US20230285402, ID # SW...)
Affinity DataIC50:  1.37nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347391(US10869871, ID # SW208496 | US20230285402, ID # SW...)
Affinity DataIC50:  1.37nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347368(US10301320, ID SW208066 | US10869871, ID # SW20806...)
Affinity DataIC50:  1.37nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347368(US10301320, ID SW208066 | US10869871, ID # SW20806...)
Affinity DataIC50:  1.37nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347368(US10301320, ID SW208066 | US10869871, ID # SW20806...)
Affinity DataIC50:  1.37nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347368(US10301320, ID SW208066 | US10869871, ID # SW20806...)
Affinity DataIC50:  1.37nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347391(US10869871, ID # SW208496 | US20230285402, ID # SW...)
Affinity DataIC50:  1.37nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266144(CHEMBL4097930)
Affinity DataIC50:  1.40nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266143(CHEMBL4070824)
Affinity DataIC50:  1.40nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347365(US10301320, ID SW206992 | US10869871, ID # SW20699...)
Affinity DataIC50:  1.41nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347365(US10301320, ID SW206992 | US10869871, ID # SW20699...)
Affinity DataIC50:  1.41nMAssay Description:This Example provides data on a group of structural analogues of SW033291. Data provided includes level of induction of a 15-PGDH-luciferase fusion g...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347365(US10301320, ID SW206992 | US10869871, ID # SW20699...)
Affinity DataIC50:  1.41nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM348758(US9790233, ID SW206992)
Affinity DataIC50:  1.41nMAssay Description:In vivo assays for 15-PGDH expression or 15-PGDH activity, e.g., ligands, agonists, antagonists, and their homologs and mimetics. The term modulator ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347365(US10301320, ID SW206992 | US10869871, ID # SW20699...)
Affinity DataIC50:  1.41nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347388(US10869871, ID # SW208488 | US20230285402, ID # SW...)
Affinity DataIC50:  1.43nMAssay Description:It is not clearly defined.More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347388(US10869871, ID # SW208488 | US20230285402, ID # SW...)
Affinity DataIC50:  1.43nMAssay Description:Assays were done by measuring the transfer of tritium from 15(S)-[15-3H] PGE2 to glutamate (at 1 μM PGE2 substrate), or by direct fluorescence m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347388(US10869871, ID # SW208488 | US20230285402, ID # SW...)
Affinity DataIC50:  1.43nMAssay Description:Each compound for inhibiting enzymatic activity of recombinant 15-PGDH in an in vitro assay. More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM556308(US11345702, Table 1.26 | US20230390274, Compound A...)
Affinity DataIC50:  1.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM347379(US10869871, ID # SW211668-(33291-R | US20230285402...)
Affinity DataIC50:  1.5nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607641(CHEMBL5220078 | US11718589, Compound 59b)
Affinity DataIC50:  1.60nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607641(CHEMBL5220078 | US11718589, Compound 59b)
Affinity DataIC50:  1.60nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607643(CHEMBL5220207 | US11718589, Compound 49b)
Affinity DataIC50:  1.70nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607637(CHEMBL5219440 | US11718589, Compound 79b)
Affinity DataIC50:  1.70nMAssay Description:This Example provides data on two groups (Table 1 and Table 2) of structural analogues of identified 15-PGDH inhibitors. Data provided is the IC50 of...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607643(CHEMBL5220207 | US11718589, Compound 49b)
Affinity DataIC50:  1.70nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50607637(CHEMBL5219440 | US11718589, Compound 79b)
Affinity DataIC50:  1.70nMAssay Description:Inhibition of 15-PGDH (unknown origin) using NAD as substrate measured for 3.5 minsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Homo sapiens (Human))
Myoforte Therapeutics

US Patent
LigandPNGBDBM50266196(CHEMBL4092806)
Affinity DataIC50:  1.80nMAssay Description:Inhibition of recombinant human C-terminal 6xHis-tagged 15-PGDH expressed in Escherichia coli using PGE2 as substrate after 15 mins in presence of NA...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 1038 total ) | Next | Last >>
Jump to: